A Reliability Tier Classification System (RTCS) for Marketed Exosome-Based Products to Facilitate Clinical Decision-Making.

BACKGROUND

Exosomes are nanosized extracellular vesicles involved in intercellular communication. The composition, regulatory status, and scientific support of commercially marketed "exosome-based" products are highly variable, creating challenges for clinicians seeking safe and evidence-informed options in dermatology and aesthetic practice.

OBJECTIVE

The Reliability Tier Classification System (RTCS) was developed to support clinical decision-making. It was designed as a framework-based tool that categorizes exosome-based products and devices intended to enhance exosome release into four reliability tiers.

METHODS

The RTCS comprises two components: (A) Descriptive Product Classification, and (B) Hierarchical Categorization Algorithm. The first component assesses four domains: (1) regulatory authorization status; (2) origin; (3) manufacturing transparency; and (4) peer-reviewed scientific evidence. The second component assigns four reliability tiers (I-IV).

RESULTS

RTCS output standardizes nomenclature for regulatory status (DRUG, MD, COS, NA), origin (AUTO, ALLO, XENO, MIM), and manufacturing reliability (composite transparency score: labeling accuracy, certification disclosure, manufacturing conditions, availability of published clinical evidence, regulatory setbacks, and availability of a detailed exosome production protocol).

CONCLUSION

This clinician-facing tool provides a structured approach to appraising marketed exosome-based products in a rapidly expanding, variably documented marketplace, not yet clinically validated. It is designed to be updateable as regulatory policies and scientific evidence evolve and may serve as a pillar for future implementation and validation.